Projects continued procedure volume growth through 2029, built on the observed 2016–2026 trend and current premium lens adoption trajectory.
Examines current LAL adoption trajectory against manufacturer pipeline data, with our editorial view on likely inflection points.
Extends the Cost Index trend forward, distinguishing premium-category price pressure from broader healthcare cost inflation.
Estimates total addressable patient population for EVO ICL against current adoption rates, with editorial commentary on structural limits to growth.